Trial Profile

Phase I Randomized Open Label Trial Investigating Adoptive Transfer of CD39+CD103+CD8+ Tumor-isolated T Cells (AGX148) Alone or Combined With siRNA Modulation of PD-1 (AGX148/PH-762) in Patients With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AGX-148 (Primary) ; PH 762 (Primary) ; Interleukin 2 replacements; Interleukin 2 replacements
Indications Advanced breast cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Solid tumours; Squamous cell cancer; Thyroid cancer
Focus Adverse reactions
Sponsors AgonOx

08 Jan 2026 Planned End Date changed from 19 May 2026 to 31 Dec 2026.
08 Jan 2026 Planned primary completion date changed from 19 May 2025 to 31 Dec 2026.
08 Jan 2026 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com